国际肿瘤学杂志最新文献

{"title":"Expressions of MMP2, TIMP2, Ki-67 and P53 in glioma tissues and their significance","authors":"Xuejuan Yu, H. An, Yamei Sun, Zheng Jiang, Xuehai Zhang, Wenjing Yang, Wei Zhang","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.12.003","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.12.003","url":null,"abstract":"Objective \u0000To investigate the expressions and significance of matrix metalloproteinase 2 (MMP2), tissue inhibitor of metalloproteinase 2 (TIMP2), Ki-67 and P53 in human glioma tissues. \u0000 \u0000 \u0000Methods \u0000The expressions of Ki-67 and P53 in paraffin samples of 50 gliomas (immunohistochemistry SP method) from January 1995 to December 2015 in Qilu Hospital of Shandong University were analyzed retrospectively, and the expressions of MMP2 and TIMP2 were detected by immunohistochemistry. The differences of parameters between high- and low-grade gliomas were compared by χ2 test and their correlations were assessed by Spearman correlation analysis. \u0000 \u0000 \u0000Results \u0000In the high-grade group (grade Ⅲ-Ⅳ, n=37), the high expression rate of MMP2 was 81.08% (30/37), the positive expression rates of Ki-67 and P53 were 78.38% (29/37) and 72.97% (27/37). In the low-grade group (grade Ⅰ-Ⅱ, n=13), there were 2 patients with high expression of MMP2, 3 patients with positive expression of Ki-67 and P53 respectively, and there were significant differences between the two groups (χ2=15.282, P<0.001; χ2=10.482, P=0.001; χ2=9.979, P=0.002). A significant correlation was found between them and pathological grade (r=0.600, P<0.001; r=0.505, P<0.001; r=0.447, P=0.001). The high expression of TIMP2 was found in 8 cases of low-grade group and 19 cases (51.35%) of high-grade group, with no significant difference (χ2=0.402, P=0.526). The expression of MMP2 was positively correlated with Ki-67 and P53 (r=0.392, P=0.005; r=0.323, P=0.022), while TIMP2 was negatively correlated with Ki-67 (r=-0.441, P=0.001). The expression of P53 was positively correlated with Ki-67 (r=0.748, P<0.001). \u0000 \u0000 \u0000Conclusion \u0000MMP2, Ki-67 and P53 may play important role in the proliferation and invasiveness of glioma. The mechanism of TIMP2 is complicated and needs further study. \u0000 \u0000 \u0000Key words: \u0000Glioma; Matrix metalloproteinase 2; Tissue inhibitor of metalloproteinase 2; Ki-67 antigen; Tumor suppressor protein P53","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"11 1","pages":"718-722"},"PeriodicalIF":0.0,"publicationDate":"2019-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84024290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular targeted therapy for advanced kidney cancer","authors":"Xiong Bobo, Jinsong Zhang, Ning-Li Li, Haifeng Wang, Yi-gang Zuo, Jiansong Wang","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.12.001","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.12.001","url":null,"abstract":"Sorafenib is the first molecularly targeted drug for first-line treatment of patients with advanced kidney cancer and has achieved satisfactory results. Since then, a variety of molecularly targeted drugs have emerged, and the treatment of patients with advanced kidney cancer has entered a new era of molecular targeting. Molecular targeted therapy improves the clinical efficacy and response rate of patients, and prolongs the progression-free survival and overall survival of patients. Current targeted drugs include vascular endothelial growth factor inhibitors, mammalian target of rapamycin, immunological checkpoint inhibitors, etc. Understanding the mechanism of action and clinical efficacy of different targeted drugs, and analyzing the challenges of current targeted drugs from the perspective of gene mutation and drug resistance are helpful to the personalized treatment of patients with advanced renal cancer. \u0000 \u0000Key words: \u0000Kidney neoplasms; Urologic neoplasms; Molecular targeted therapy; Antineoplastic agents; Precision medicine","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"80 1","pages":"705-710"},"PeriodicalIF":0.0,"publicationDate":"2019-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83186132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study on the molecular mechanism of miR-200b-3p regulates the proliferation, invasion, migration and apoptosis of pancreatic cancer cells by down-regulating VEGFA","authors":"刘慧纯 张家耀 李伟 李庆贺, Liu Huichun Zhang Jiayao Li Wei Li Qinghe","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.11.002","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.11.002","url":null,"abstract":"Objective \u0000To explore the molecular mechanism of miR-200b-3p regulates the proliferation, invasion, migration and apoptosis of pancreatic cancer cells by targeting vascular endothelial growth factor A (VEGFA). \u0000 \u0000 \u0000Methods \u0000The expression of miR-200b-3p in pancreatic cancer tissues and cell lines was detected by quantitative real-time fluorescence PCR (qRT-PCR). Pancreatic cancer PANC-1 cells were divided into NC group, miR-200b-3p mimic group, si-VEGFA group and si-VEGFA+ miR-200b-3p inhibitor group. The proliferation, migration and invasion of PANC-1 cells were measured by CCK-8 and Transwell assay. The apoptosis of PANC-1 cells was detected by Annexin V-FITC/PI double staining flow cytometry assay. The targeted relationship of miR-200b-3p and VEGFA was estimated by dual luciferase reporter gene assay and Western blotting. \u0000 \u0000 \u0000Results \u0000The expression of miR-200b-3p in pancreatic cancer tissues and cell lines was decreased. After miR-200b-3p was overexpressed in PANC-1 cells for 48 h, the cell viabilities of PANC-1 cells in NC group and miR-200b-3p mimic group were 1.250±0.028 and 0.983±0.044, the numbers of migrated cells were 402.700±21.530 and 158.000±17.620, the numbers of invaded cells were 478.300±31.050 and 170.000±32.470, and the cell apoptosis rates were (5.280±0.352)% and (7.430±0.393)%. The cell viability, migration and invasion of PANC-1 cells in miR-200b-3p mimic group were significantly decreased than those in NC group (t=5.060, P=0.007; t=8.796, P=0.001; t=6.863, P=0.002). The cell apoptosis rate in miR-200b-3p mimic group was significantly higher than that in NC group (t=4.076, P=0.015). The fluorescence intensity in VEGFA-WT group was 1.000±0.027, which was significantly higher than that in VEGFA-WT+ miR-200b-3p mimic group (0.632±0.048; t=6.637, P=0.003). The fluorescence intensities in VEGFA-MUT group and VEGFA-MUT + miR-200b-3p mimic group were 1.000±0.049 and 0.868±0.047, with no statistically significant difference (t=1.944, P=0.124). After miR-200b-3p was overexpressed in PANC-1 cells for 48 h, the expressions of VEGFA in NC group and miR-200b-3p mimic group were 1.000±0.058 and 0.762±0.020, respectively. The expression level in miR-200b-3p mimic group was lower than that in NC group (t=3.908, P=0.017). After transfection of PANC-1 cells with si-VEGFA or si-VEGFA + miR-200b-3p inhibitor for 48 h, the cell viabilities of PANC-1 cells in NC group, si-VEGFA group and si-VEGFA + miR-200b-3p inhibitor group were 1.300±0.058, 0.943±0.047 and 1.143±0.023, the numbers of migrated cells were 446.000±17.350, 206.300±19.360 and 428.300±30.330, and the numbers of invaded cells were 510.300±24.550, 175.700±24.290 and 473.700±35.530, with statistically significant differences (F=15.830, P=0.004, F=33.530, P=0.001, F=38.860, P<0.001). The cell viability, migration and invasion of PANC-1 cells in si-VEGFA group were significantly decreased than those in NC group (P=0.003, P<0.001, P<0.001). There was no significant difference between si-","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"23 1","pages":"649-656"},"PeriodicalIF":0.0,"publicationDate":"2019-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77795074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress of external beam radiotherapy for thyroid cancer","authors":"D. Fang, Xu Jincai, Wang Yunsheng, Liu Qinjiang","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.11.001","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.11.001","url":null,"abstract":"External beam radiotherapy (EBRT) is one of the important treatment of thyroid cancer. EBRT is still controversial in some aspects of differentiated thyroid cancer. With the development of radiotherapy technology, improvement of equipment and accuracy, treatment complications caused by EBRT are significantly reduced. As a result, EBRT is valued again in the treatment of thyroid cancer, and its indications have been broadened. How to improve the curative effect and guarantee the quality of life becomes the focus of attention. EBRT may be an effective treatment for specific stage and pathological type of thyroid cancer. The multidisciplinary approach is expected to benefit more patients in the future. \u0000 \u0000 \u0000Key words: \u0000Thyroid neoplasms; Antineoplastic protocols; Radiotherapy","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"31 1","pages":"641-648"},"PeriodicalIF":0.0,"publicationDate":"2019-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81733126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The landscape of palliative systemic therapy and overall survival analysis of elderly patients with advanced breast cancer in China National Cancer Center","authors":"Guan Xiuwen, Ma Fei, X. Binghe","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.11.003","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.11.003","url":null,"abstract":"Objective \u0000To compare the survival data of elderly advanced breast cancer (ABC) patients in China National Cancer Center with USA and summarize the therapeutic characteristics in elderly ABC patients via real world study. \u0000 \u0000 \u0000Methods \u0000We summarized the clinicopathological characteristics, therapeutic regimens and survival outcome of 1 425 females with ABC who were initially hospitalized between January 2003 and December 2013 from Database in China National Cancer Center and compared with 21 185 ABC patients in the Surveillance, Epidemiology, and End \u0000 \u0000 \u0000Results \u0000(SEER) database. Results The median overall survival (OS) of elderly patients was significantly shorter than that of the young group in China National Cancer Center (35.5 months vs. 43.9 months; χ2=8.747, P=0.003), which was similar to the survival feature in SEER database (24.0 months vs. 36.0 months; χ2=540.227, P<0.001). Compared with the young population, significantly more elderly patients suffered from the medical complications of hypertension [30.3% (67/221) vs. 9.5% (114/1 204); χ2=73.073, P<0.001], diabetes [14.5% (32/221) vs. 4.7% (57/1 204); χ2=30.220, P<0.001] and heart disease [6.3% (14/221) vs. 1.7% (20/1 204); χ2=17.638, P<0.001]. In estrogen receptor (ER) and/or progesterone receptor (PR)-positive patients, the percentage of receiving first-line endocrine therapy in elderly patients was significantly larger than that of the young population [26.9% (43/160) vs. 9.5% (80/841); χ2=37.599, P<0.001]. Moreover, in ER and/or PR-positive population, the elderly patients underwent first-line endocrine therapy resulted in better OS than those underwent first-line chemotherapy (49.9 months vs. 32.6 months; χ2=4.774, P=0.029), while no significant difference was observed between these two therapeutic modes in the young population (56.9 months vs. 48.8 months; χ2=1.103, P=0.294). \u0000 \u0000 \u0000Conclusion \u0000The proportion of elderly ABC patients with the medical complication of hypertension, diabetes and heart disease is significantly larger than that of the young population, which may lead to the difference in treatment decision making. In ER and/or PR-positive elderly ABC patients, receiving first-line endocrine therapy may result in better survival than first-line chemotherapy. \u0000 \u0000 \u0000Key words: \u0000Breast neoplasms; Aged; Therapy; Drug therapy","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"38 1","pages":"657-661"},"PeriodicalIF":0.0,"publicationDate":"2019-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83781650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and survival analysis of TACE combined with radiofrequency ablation in the treatment of liver metastasis from colorectal cancer","authors":"X. Yi, T. Yan, Ding Bo, Liu Yuanzhi, L. Dongyang, Zhang Yan","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.11.006","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.11.006","url":null,"abstract":"Objective \u0000To observe the clinical efficacy and safety of transhepatic arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in the treatment of colorectal cancer with liver metastasis. \u0000 \u0000 \u0000Methods \u0000The data of 92 patients with colorectal cancer with liver metastasis admitted to Nanyang First People′s Hospital of Henan Province from January 2014 to January 2016 were retrospectively analyzed. A total of 46 patients treated with TACE were selected as the TACE group, and another 46 patients treated with TACE and RFA were selected as the combined group. The clinical efficacies of the two groups were compared, and the changes of Karnofsky functional status (KPS) scores before and after treatment in the two groups were analyzed. The incidences of complications in the two groups were calculated. Patients in the two groups were followed up, and the progress-free survival (PFS) and overall survival (OS) were calculated. \u0000 \u0000 \u0000Results \u0000The disease control rate of the combined group was 82.61% (38/46), and that of the TACE group was 63.04% (29/46). The disease control rate of the combined group was higher than that of the TACE group (χ2=4.449, P=0.035). Before treatment, the KPS scores of the combined group and the TACE group were 71.84±4.37, 72.22±4.26, with no statistically significant difference (t=0.423, P=0.673). After treatment, the KPS scores of the two groups were higher than those before treatment, and the KPS score of the combined group was higher than that of the TACE group (79.81±6.15 vs. 75.86±6.02; t=3.108, P=0.003). The incidence of complications was 54.35% (25/46) in the combined group and 41.30% (19/46) in the TACE group. The difference between the two groups was not statistically significant (χ2=1.568, P=0.210). The median PFS and OS in the TACE group were 12.6 and 20.7 months, and those in the combined group were 18.9 and 28.2 months. The PFS and OS of the combined group were longer than those of the TACE group (χ2=72.025, P<0.001; χ2=26.580, P<0.001). \u0000 \u0000 \u0000Conclusion \u0000TACE combined with RFA is effective in the treatment of liver metastasis of colorectal cancer, which can effectively improve the KPS score of patients, prolong the PFS and OS, and do not increase the risk of complications. \u0000 \u0000 \u0000Key words: \u0000Colorectal neoplasms; Neoplasm metastasis; Hepatic arterial chemoembolization; Radiofrequency ablation; Survival analysis","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"90 1","pages":"673-677"},"PeriodicalIF":0.0,"publicationDate":"2019-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89061885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of 5-hydroxytryptamine and receptors in tumorigenesis","authors":"Li Yang, Li Zhongxin, Jia Yitao","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.11.008","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.11.008","url":null,"abstract":"The role of 5-hydroxytryptamine (5-HT) has attracted more and more attention in the development of tumor. In addition to the synthesis of 5-HT by enterochromaffin cells, some tumor cells and immune cells can also secrete 5-HT, and there are different 5-HT receptors on the surface of these cells. 5-HT plays multiple biological effects through activating different receptors. 5-HT promotes the proliferation and invasion of tumor and induces the angiogenesis of tumor tissues through activating its corresponding receptors, such as 5-HT1D, and so on. Furthermore, various 5-HT receptors are expressed on the surface of immune cells. On the one hand, physiological doses of 5-HT promote the proliferation and secretion of immune cells. On the other hand, pathologic 5-HT has an effect on inducing the differentiation of immune cells in the direction of immunosuppression, thus participating in the occurrence and development of tumor. \u0000 \u0000 \u0000Key words: \u0000Serotonin; Receptors; Immunity; Neoplasms","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"132 1","pages":"682-685"},"PeriodicalIF":0.0,"publicationDate":"2019-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86336854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress of radiotherapy for vulvar cancer","authors":"Zhang Baoyou, Wang Tiejun","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.11.012","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.11.012","url":null,"abstract":"Radiation therapy has a major role in curative treatment of vulvar cancer patients including preoperative radiotherapy, radical radiotherapy and postoperative radiotherapy. Radiation therapy with concurrent chemotherapy may be able to achieve better clinical outcomes, but the rate of acute and chronic toxicities may be higher. So we should develop individual radiotherapy and chemotherapy program, strictly limit the dose and avoid treatment interruption. It is recommended to apply intensity-modulated radiotherapy, which is supe-rior to conventional radiotherapy in dose and clinical efficacy. Interstitial brachytherapy can be used selectively, but it requires a high level of surgical experience, and the doses to target and organs at risk need to be further discussed. \u0000 \u0000 \u0000Key words: \u0000Vulvar neoplasms; Radiotherapy; Antineoplastic combined chemotherapy protocols; Intensity modulated radiation therapy","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"46 1","pages":"699-704"},"PeriodicalIF":0.0,"publicationDate":"2019-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73919676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression and function of CNPY2 in tumors","authors":"Qu Zhen-jie, C. Qin","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.11.010","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.11.010","url":null,"abstract":"In order to satisfy the nutritional supply, neovascularization is needed in the growth of tumors. At present, anti-angiogenesis is one of the important directions in the research and development of anti-cancer drugs. CNPY2 is a new secretory angiogenic factor, which may participate in the occurrence and deve-lopment of tumors by promoting angiogenesis. CNPY2 is abnormally expressed in a variety of tumors, and it may be a new target for diagnosis and treatment of tumors. \u0000 \u0000 \u0000Key words: \u0000Neoplasms; CNPY2","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"96 1","pages":"692-694"},"PeriodicalIF":0.0,"publicationDate":"2019-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78766286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research and application of PD-1/PD-L1 inhibitors in small cell lung cancer","authors":"李桂香 杜明丽 赵磊 吴文娟, Li Guixiang Du Mingli Zhao Lei Wu Wenjuan","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.11.011","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.11.011","url":null,"abstract":"Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a very high degree of malignancy. Currently, the standard treatment for SCLC is still chemoradiotherapy, and although SCLC is sensitive to chemotherapy in the early stage, recurrence and metastasis often occur due to drug resis-tance. In recent years, immunotherapy has made some progress in the study of SCLC. The immunodetection point programmed death-1 (PD-1) and its ligand (PD-L1) inhibitors, such as nivolumab, atezolizumab and pabolizumab, have shown good antitumor activity in clinical studies of SCLC, and PD-1/PD-L1 inhibitors combined with chemotherapy have shown better efficacy, providing a new strategy for the treatment of SCLC. \u0000 \u0000 \u0000Key words: \u0000Small cell lung carcinoma; Immunotherapy; PD-1/PD-L1","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"239 1","pages":"695-698"},"PeriodicalIF":0.0,"publicationDate":"2019-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80354527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}